PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
180 Life Sciences Corp. (ATNF)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS68236V1044
CUSIP68236V104
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.01M
EPS-$269.80
EBITDA (TTM)-$17.54M
Year Range$2.61 - $37.81
Target Price$80.00
Short %2.60%
Short Ratio0.58

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ATNF

180 Life Sciences Corp.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in 180 Life Sciences Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%OctoberNovemberDecember2024FebruaryMarch
-99.94%
117.18%
ATNF (180 Life Sciences Corp.)
Benchmark (^GSPC)

S&P 500

Returns By Period

180 Life Sciences Corp. had a return of -42.70% year-to-date (YTD) and -93.22% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-42.70%10.16%
1 month-37.11%3.47%
6 months-79.73%22.20%
1 year-93.22%30.45%
5 years (annualized)-77.45%13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-0.00%-13.43%
2023-29.04%-8.10%-29.85%-36.98%-21.03%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for 180 Life Sciences Corp. (ATNF) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ATNF
180 Life Sciences Corp.
-0.77
^GSPC
S&P 500
2.79

Sharpe Ratio

The current 180 Life Sciences Corp. Sharpe ratio is -0.77. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.77
2.79
ATNF (180 Life Sciences Corp.)
Benchmark (^GSPC)

Dividends

Dividend History


180 Life Sciences Corp. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-99.95%
0
ATNF (180 Life Sciences Corp.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the 180 Life Sciences Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 180 Life Sciences Corp. was 99.96%, occurring on Mar 26, 2024. The portfolio has not yet recovered.

The current 180 Life Sciences Corp. drawdown is 99.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.96%Apr 13, 2021744Mar 26, 2024
-80.87%Jun 23, 2020106Nov 19, 202096Apr 12, 2021202
-6.72%Mar 4, 202011Mar 18, 202011Apr 2, 202022
-3.68%Nov 5, 201911Nov 19, 201916Dec 12, 201927
-1.53%Jul 7, 201728Aug 15, 2017118Feb 2, 2018146

Volatility

Volatility Chart

The current 180 Life Sciences Corp. volatility is 51.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%OctoberNovemberDecember2024FebruaryMarch
51.75%
2.80%
ATNF (180 Life Sciences Corp.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of 180 Life Sciences Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items